Evidence Review Committee Relationships With Industry and Other Entities (Comprehensive)— 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (October 2017)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational or Other Financial Benefit	Expert Witness
Fred M. Kusumoto <i>(Chair)</i>	Mayo Clinic—Director, Pacing and Electrophysiology Service	None	None	None	None	None	None
Kent R. Bailey (Vice Chair)	Mayo Clinic—Professor, Health Sciences Research	None	None	None	 Novartis (DSMB)* NHLBI (DSMB) NHLBI (DSMB)† 	None	None
Ahmad Sami Chaouki	Northwestern University Feinberg School of Medicine—Assistant Professor, Department of Pediatrics, Division of Cardiology	None	None	None	None	None	None
Abhishek J. Deshmukh	Mayo Clinic—senior Associate Consultant, Associate Professor	None	None	None	None	None	None
Sandeep Gautam	University of Missouri Health Care—Assistant Professor of Clinical Medicine, Division of Cardiovascular Medicine	None	None	None	None	• Pfizer‡	None
Robert Kim	University of Florida; Health Science Center Jacksonville—Assistant Professor of Medicine	None	None	None	None	None	None

Daniel Bruce Kramer	Beth Israel Deaconess Medical Center; Harvard Medical School— Assistant Professor of Medicine	None	None	None	 NIH* Greenwall Foundation* 	 Baim Clinical Research Institute* 	 Plaintiff, EP intervention (pacemaker), 2015 Plaintiff, EP intervention (ablation), 2015
Litsa K. Lambrakos	University of Miami, Miller School of Medicine— Assistant Professor of Medicine	None	None	None	None	None	None
Naseer H. Nasser	South Bend Clinic— Attending Cardiac Electrophysiologist	None	None	None	None	None	None
Dan Sorajja	Mayo Clinic Arizona Cardiovascular Diseases— Assistant Professor of Medicine	None	None	None	None	Boston Scientific§MallinckrodtMilestone	None

This table represents all relationships of evidence review committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of \geq 5% of the voting stock or share of the business entity, or ownership of \geq 55,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Evidence Review Committee

*Significant relationship.

⁺No financial benefit.

‡Dr. Gautam is a clinical trial enroller for the EMANATE trial funded by Pfizer. All appropriate firewalls are in place so this relationship was determined not relevant. §Dr. Sorajja is a clinical trial enroller for the UNTOUCHED trial funded by Boston Scientific. All appropriate firewalls are in place so this relationship was determined not relevant.

ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; HRS, Heart Rhythm Society; NIH, National Institutes of Health; and NHLBI, National Heart, Lung, and Blood Institute.

© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society.